Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

16164 reported adverse events

Drugs of this class: VALGANCICLOVIR GANCICLOVIR

These side effects are most commonly reported by patients taking drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class:

#	Side effect	Count
0	OFF LABEL USE	1965
1	CYTOMEGALOVIRUS INFECTION	1702
2	DRUG INEFFECTIVE	1385
3	PYREXIA	976
4	NEUTROPENIA	871
5	DIARRHOEA	808
6	PRODUCT USE IN UNAPPROVED INDICATION	771
7	LEUKOPENIA	753
8	DRUG RESISTANCE	688
9	CYTOMEGALOVIRUS VIRAEMIA	671

See all common reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

Drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	CYTOMEGALOVIRUS SYNDROME	78	0.5417
1	ENCEPHALITIS CYTOMEGALOVIRUS	124	0.4247
2	SMOOTH MUSCLE CELL NEOPLASM	94	0.3790
3	CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION	80	0.3448
4	CYTOMEGALOVIRUS OESOPHAGITIS	66	0.2374
5	CYTOMEGALOVIRUS VIRAEMIA	671	0.2178
6	DELAYED GRAFT FUNCTION	119	0.2129
7	CYTOMEGALOVIRUS ENTERITIS	56	0.1993
8	CYTOMEGALOVIRUS CHORIORETINITIS	234	0.1565
9	PARVOVIRUS B19 INFECTION	71	0.1537

See all enriched reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]